The standalone pharmacy business sustained its momentum in Q2FY16 with 34% growth in revenues on a YoY basis. The EBITDA margin stood at 3.6% in H1FY16. This was after absorbing the cost of Hetero Pharmacy following the integration, as well as from the ongoing efforts to rationalize costs which have yielded results. Excluding Hetero network, the EBITDA margin is at 3.7% in H1FY16 as compared to 3.2% in H1FY15.